FILIP JANKU to Response Evaluation Criteria in Solid Tumors
This is a "connection" page, showing publications FILIP JANKU has written about Response Evaluation Criteria in Solid Tumors.
Connection Strength
0.339
-
Phase Ib Study of Combination Therapy with MEK Inhibitor Binimetinib and Phosphatidylinositol 3-Kinase Inhibitor Buparlisib in Patients with Advanced Solid Tumors with RAS/RAF Alterations. Oncologist. 2020 01; 25(1):e160-e169.
Score: 0.170
-
Liquid Biopsy Response Evaluation Criteria in Solid Tumors (LB-RECIST). Ann Oncol. 2024 Mar; 35(3):267-275.
Score: 0.058
-
Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine. J Hematol Oncol. 2019 12 30; 12(1):145.
Score: 0.044
-
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer. Cancer Chemother Pharmacol. 2016 05; 77(5):1097-102.
Score: 0.034
-
Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. Cancer Chemother Pharmacol. 2016 05; 77(5):973-7.
Score: 0.034